Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Update

Elevai Labs, Inc. (NASDAQ:ELAB) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 263,000 shares, a growth of 438.9% from the November 30th total of 48,800 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is presently 0.2 days.

Elevai Labs Stock Up 1.2 %

NASDAQ ELAB traded up $0.03 during trading hours on Friday, hitting $2.44. 307,202 shares of the company traded hands, compared to its average volume of 326,737. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.40 and a current ratio of 3.86. The business’s 50-day moving average is $5.92 and its 200-day moving average is $48.58. The stock has a market capitalization of $6.31 million and a price-to-earnings ratio of -0.04. Elevai Labs has a twelve month low of $1.74 and a twelve month high of $778.00.

Institutional Investors Weigh In On Elevai Labs

An institutional investor recently bought a new position in Elevai Labs stock. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of Elevai Labs, Inc. (NASDAQ:ELAB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 80,666 shares of the company’s stock, valued at approximately $47,000. Whittier Trust Co. of Nevada Inc. owned about 0.43% of Elevai Labs at the end of the most recent reporting period. Institutional investors and hedge funds own 22.22% of the company’s stock.

About Elevai Labs

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.